Forecast

There is no analyst data available for this company.

News Go to news feed

Lifecare reduces operating loss in Q2 2026 and secures financing until Q2 2027

Lifecare reports an operating loss of NOK 10.6m for Q2 2026 versus NOK 22m in the prior year and improved liquidity of NOK 37m. Revenue remained minimal at NOK 250,000, coming from a government grant; net profit of NOK 4.5m resulted from revaluations and the deconsolidation of the German subsidiary. Management plans to relocate and build a controlled production facility in Bergen as a prerequisite for the CE submission; financial runway is expected to last until Q2 2027, but a CE timeline in 2027 remains uncertain. » More on de.investing.com

Financials

In the last quarter, LIFECARE AS NOK 0,40 had revenue of €22.89K and net profit of €439.27K

(EUR)	June 2026	YoY
Revenue	22.89K	3,786.34%
Gross profit	22.89K	3,786.34%
Net profit	439.27K	139.22%
EBITDA	-950.49K	45.68%

Fundamentals

Metric	Value
Market capitalization	€591.58K
Number of shares	19.09M
52-week high/low	€1.04 - €0.025
Dividends	No
Beta	-0.43
P/E ratio	-0.08
PEG ratio	0.00
P/B ratio	2.46
P/S ratio	3.82

Company profile

Lifecare AS beschäftigt sich mit der Erforschung und Entwicklung von medizinischen Sensoren für die Gesundheitsüberwachung in Norwegen. Es entwickelt Sencell, einen Mikrosensor zur Überwachung des Blutzuckerspiegels bei Patienten mit Diabetes. Das Unternehmen wurde 2006 gegründet und hat seinen Hauptsitz in Bergen, Norwegen.